Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F07%3A00022773" target="_blank" >RIV/00216224:14110/07:00022773 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide

Original language description

The aim of this prospective study is to investigate if Thalidomide is able to antagonize the impact of cytogenetic negative prognostic markers. We have focused on four chromosomal aberrations known as negative prognostic factors in multiple myeloma (MM)treated by conventional or myeloablastive treatment: deletion of 13q14 (RB), deletion of 17p13 (p53), amplification of CKS1B gene (1q21) and translocation t(4;14). Material and Methods: For identification of malignant plasma cells in bone marrow samples,we use cytoplasmic immunoglobulin (cIg) labelling methodology. This method allows us to identify simultaneously monotypic plasma cells by monoclonal antibody fluorescence (anti-k or anti-l) and to detect chromosomal abnormalities by fluorescence in situhybridization (cIg-FISH). Overall characteristics of up-to-date set of 24 patients (pts.): median age 65,0 years (range 48,3-83,3). 66% (16/24 pts.) in stage IIIA, 29% (7/24 pts.) in stage IIA and 1 patient in IIIB. 75% (16/24 pts.) were

Czech name

Prognostický význam vybraných chromozomálních aberací u pacientů s mnohočetným myelomem léčených thalidomidem

Czech description

Význam delece RB a p53, translokace t(4;14) a amplifikace 1q21, negativních prognostických faktorů při konvenční terapii, u pacientů s mnohočetným myelomem léčených thalidomidem.

Type

D - Article in proceedings

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/LC06027" target="_blank" >LC06027: University Research Centre - Czech Myeloma Group</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2007

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection

Haematologica

ISBN

—

ISSN

0390-6078

e-ISSN

—

Number of pages

1

Pages from-to

170

Publisher name

Ferrata-Storti foundation

Place of publication

Pavia (Italy)

Event location

Kos Island, Greece

Event date

Jul 25, 2007

Type of event by nationality

EUR - Evropská akce

UT code for WoS article

—